Shionogi Ltd appoints Star for UK launch

Paul Hudson is to succeed Olivier Brandicourt as Chief Executive Officer at Sanofi. 

Star is delighted to be partnering with specialist research-driven Japanese pharma company, Shionogi & Co., Ltd., as they launch a new product into the UK market.

In the year they celebrated their 140th anniversary, Shionogi engaged Star to run the initial promotion over 12 months to attract, recruit and deploy high-quality market access and commercial sales resource to facilitate the launch of a women’s health product in the UK.

Founded in Osaka in 1878, Shionogi’s entrepreneurial spirit and corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve”, combined with its focus on the development and commercialisation of high-quality medicines, makes the partnership a very exciting one for Star.

In 2012 Shionogi launched its European Headquarters in London and is at an early stage in its development as an operational entity that can commercialise its own drugs. Their pipeline focuses on infectious disease, pain, CNS and oncology.

Star were chosen as preferred partner on the basis of the company’s ability to provide the very best talent to the Shionogi organisation, its flexibility of approach, and the governance applied to the project in order to meet the needs of the business.

Operations Director at Star, Mark Ward, said: “Star are delighted to help and support Shionogi UK in the build of a commercial salesforce.

“We are excited to be the partner of choice from the early phase of the UK operation and will provide the high-quality individuals desired to ensure a successful product launch in late 2018 and beyond.”